Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
346 EUR | +2,22% | +4,69% | -3,76% |
20/03 | Transcript : Virbac SA, 2023 Earnings Call, Mar 20, 2024 | |
19/03 | Virbac SA geeft winstverwachting voor het jaar 2024 | CI |
Vakgebied
- medicijnen voor huisdieren: tegen parasieten, vaccins, antibiotica, verdovingsmiddelen, ontstekingremmers, producten voor tandverzorging, producten voor oogheelkunde en dermatologie voor honden, katten, paarden, vogels, knaagdieren, enz. Verder verkoopt het concern voeding en elektronische identificatiechips;
- medicijnen voor fokdieren: producten tegen parasieten en antibiotica bestemd voor runderen, schapen, varkens, gevogelte, enz.;
De geografische verdeling van de omzet is als volgt: Frankrijk (15,8%), Europa (24,9%), Azië (17,5%), Latijns-Amerika (16,2%), Noord-Amerika (13,3%), Stille Oceaan (9,7%), Afrika en Midden-Oosten (2,6%).
Aantal werknemers: 5 459
Verkoop per activiteit
EUR in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Production Animals - Other Ruminants
16,8
%
| 172 | 16,2 % | 204 | 16,8 % | +18,56% |
Pets- Specialties
10,9
%
| 112 | 10,5 % | 133 | 10,9 % | +19,10% |
Pets - Parasiticides
10,1
%
| 108 | 10,2 % | 123 | 10,1 % | +13,38% |
Pets - Others
10,1
%
| 101 | 9,5 % | 122 | 10,1 % | +20,85% |
Pets - Antibiotics/Dermatology
9,1
%
| 101 | 9,5 % | 111 | 9,1 % | +9,61% |
Pets - Specialized Food
8,1
%
| 78 | 7,4 % | 99 | 8,1 % | +25,64% |
Production Animals - Bovine Antibiotics
7,1
%
| 81 | 7,6 % | 86 | 7,1 % | +6,04% |
Pets - Immunology
7,0
%
| 77 | 7,2 % | 85 | 7,0 % | +10,79% |
Production Animals - Bovine Parasiticides
6,2
%
| 58 | 5,4 % | 76 | 6,2 % | +31,77% |
Production Animals - Aquaculture
3,6
%
| 48 | 4,5 % | 44 | 3,6 % | -6,93% |
Production Animals - Other Pig/Poultry
3,0
%
| 33 | 3,1 % | 37 | 3,0 % | +9,28% |
Pets - Equine
2,8
%
| 32 | 3,0 % | 34 | 2,8 % | +6,01% |
Production Animals - Pig/Poultry Antibiotics
2,6
%
| 35 | 3,3 % | 32 | 2,6 % | -7,51% |
Other
2,6
%
| 29 | 2,7 % | 32 | 2,6 % | +10,42% |
Verkoop per regio
EUR in miljoen | 2021 | Gewicht | 2022 | Gewicht | Delta |
---|---|---|---|---|---|
Europe (excluding France)
24,9
%
| 281 | 26,4 % | 303 | 24,9 % | +7,75% |
Asia
17,5
%
| 184 | 17,2 % | 213 | 17,5 % | +16,04% |
Latin America
16,2
%
| 167 | 15,7 % | 197 | 16,2 % | +18,05% |
France
15,8
%
| 185 | 17,4 % | 192 | 15,8 % | +3,85% |
North America
13,3
%
| 124 | 11,7 % | 162 | 13,3 % | +30,38% |
Pacific
9,7
%
| 94 | 8,9 % | 118 | 9,7 % | +24,75% |
Africa & Middle East
2,7
%
| 30 | 2,8 % | 32 | 2,7 % | +9,33% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 01-01-06 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 01-02-16 |
Sophie Favini
COO | Chief Operating Officer | - | 01-07-23 |
Chief Tech/Sci/R&D Officer | - | 01-05-94 | |
Sandrine Brunel
IRO | Public Communications Contact | - | 01-11-98 |
Michel Garaudet
IRC | Investor Relations Contact | 69 | 01-12-02 |
Marc Bistuer
PRN | Corporate Officer/Principal | 63 | 15-12-20 |
Human Resources Officer | - | 01-05-15 | |
Nathalie Pollet
SAM | Sales & Marketing | - | 01-01-93 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 65 | 01-01-11 | |
Philippe Capron
BRD | Director/Board Member | 64 | 01-01-04 |
Chairman | 59 | 01-01-98 | |
Director/Board Member | 63 | 01-01-95 | |
Director/Board Member | 53 | 18-06-19 | |
Director/Board Member | 30 | 05-09-17 | |
Sylvie Gueguen
BRD | Director/Board Member | 59 | 30-10-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 8 458 000 | 4 193 763 ( 49,58 %) | 14 938 ( 0,1766 %) | 49,58 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
VIRBAC 0.19% | 15 852 | 0.19% | 5 695 208 $ |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Bio Veto Tests SA
Bio Veto Tests SA Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Bio Veto Tests SA is a French company that develops vaccines against viral and parasitic diseases in companion animals. The private company is based in Sanary sur Mer, France. Bio Veto Tests was acquired by Virbac SA on May 07, 2003. |
Pharmaceuticals: Major
|
Virbac Nutrition SAS
Virbac Nutrition SAS Food: Specialty/CandyConsumer Non-Durables Part of Virbac SA, Virbac Nutrition SAS is a French company that manufactures and wholesales pet food. The private company is based in Vauvert, France. The company was founded in 1987. Philippe Domptail has been the CEO of the company since 2011. |
Food: Specialty/Candy
|
Virbac (Australia) Pty Ltd.
Virbac (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Virbac (Australia) Pty Ltd. is an Australian company that manufactures veterinary pharmaceuticals and vaccines. The private company is based in Milperra, Australia. |
Pharmaceuticals: Major
|
Virbac RSA (Pty) Ltd.
| |
Virbac Animal Health India Pvt Ltd.
| |
Virbac Ltd.
Virbac Ltd. Medical DistributorsDistribution Services Part of Virbac SA, Virbac Ltd. is a British company that wholesales pharmaceutical products. The private company is based in Bury St. Edmunds, UK. Founded in 1986. |
Medical Distributors
|
Virbac New Zealand Ltd.
Virbac New Zealand Ltd. Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Virbac New Zealand Ltd. is a New Zealander company that manufactures medicines for animals. The private company is based in Auckland, New Zealand. |
Pharmaceuticals: Major
|
Virbac Mexico SA de CV
Virbac Mexico SA de CV Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Virbac Mexico SA de CV is a Mexican pharmaceutical company that manufactures pharmaceutical products. The private company is based in Guadalajara, Mexico. |
Pharmaceuticals: Major
|
Virbac Danmark A/S
|
Sector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,76% | 3,07 mld. | |
-14,27% | 77,16 mld. | |
+9,26% | 7,97 mld. | |
+4,62% | 3,09 mld. | |
-21,25% | 1,31 mld. | |
+9,80% | 1,29 mld. | |
-20,24% | 1,29 mld. | |
-2,83% | 1,28 mld. | |
-14,08% | 1,11 mld. | |
+4,89% | 971 mln. |
- Beurs
- Aandelen
- Aandeel Virbac - Euronext Paris
- Onderneming Virbac